Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

This study tests a combination of two drugs — tocilizumab (an anti-inflammatory medication used in arthritis) and atezolizumab (an immunotherapy) — in adults with advanced non-small cell lung cancer (NSCLC) that stopped responding to first-line immunotherapy treatment. **You may be eligible if...** - You are 18 or older with stage IV or recurrent non-squamous NSCLC - Your most recent treatment included an immunotherapy checkpoint inhibitor (such as pembrolizumab or nivolumab) - You are in reasonable physical condition (ECOG 0–2) - You have had at least one prior line of treatment **You may NOT be eligible if...** - Your cancer has a treatable driver mutation (like EGFR or ALK) for which targeted therapies exist - Your prior immunotherapy caused severe (grade 3 or higher) side effects - You have an autoimmune disease or interstitial lung disease (IPF) - You have untreated or progressing brain metastases - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.